Scientific Advisory Council
We are very pleased that some of the most distinguished senior researchers in the field of psychiatry have joined our Scientific Advisory Council.
Members of the Juvenile Bipolar Research Foundation’s Scientific Advisory Council assist the foundation in reviewing applications, and will act as primary reviewers of grant proposals under consideration by the consortium for funding. Scientific Advisory Council members serve as consultants to review the Foundation’s entire research portfolio and to identify promising new areas of research. Appointments to this board are for a term of five years.
Ross J. Baldessarini, M.D. is an internationally known neuroscientist and research psychopharmacologist who has made many contributions related to the basic scientific understanding of central monoaminergic systems, their involvement in the pathophysiology of neuropsychiatric disorders, and the interactions of antipsychotic and mood-altering agents with them.
His recent interests have been directed particularly toward central dopaminergic systems of the brain and their relevance to the actions, side effects, development, and clinical application of antipsychotic and antimanic agents.
Dr. Baldessarini has been a Career Investigator of the NIMH since 1970, and the author of over 1,350 publications, including the chapters on psychopharmacology in Goodman & Gilman’s standardAmerican Textbook of Pharmacology, as well as his own classic text, Chemotherapy in Psychiatry: Principles and Practice (Harvard University Press), and serves on editorial boards of several leading neuroscience and psychiatric journals. Among his many recognitions was election to the Scholars of Johns Hopkins University.
In 1988, Professor Baldessarini was named permanent Director of the Laboratories for Psychiatric Research as well as Director of the new Bipolar & Psychotic Disorders Program which he founded and, in 1989, also became Co-Director of Psychopharmacology and Psychopharmacology Training at the McLean Psychiatric Division of MGH. He has directed that Program since 1996.
Dr. Baldessarini is a tenured Professor of Psychiatry and in Neuroscience at Harvard Medical School and Senior Consulting Psychiatrist at MGH. He founded the International Consortium for Bipolar Disorder Research in 1995 with colleagues from the US, Canada and Europe, and serves as a consultant to numerous scientific, industrial, and clinical organizations. Ross J. Baldessarini has been very active the education of a generation of medical trainees and psychiatrists in psychopharmacology and other biological aspects of psychiatry, as well as training over 130 basic and clinical researchers. He is widely regarded as having an unusually broad and critical perspective on the integration of basic research in neuroscience and pharmacology with problems in clinical research and contemporary psychiatric practice.
Frederick K. Goodwin, M.D.
Frederick K. Goodwin, M.D., is Research Professor of Psychiatry at The George Washington University and Director of the University’s Psychopharmacology Research Center where he conducts research on manic-depressive illness. He also directs the Center on Neuroscience, Medical Progress, and Society at the George Washington University Medical Center. At the Center, Dr. Goodwin’s policy studies focus on the impact of changing patterns of health care on quality and innovation in medicine.
Dr. Goodwin is the former Director of the National Institute of Mental Health (NIMH), the largest research and research training institution in the world dedicated to the application of biological, behavioral, and social science to the treatment and prevention of mental illness and refinement of mental health services. Prior to that, he held a Presidential appointment as head of the Alcohol, Drug Abuse, and Mental Health Administration.
Dr. Goodwin is a recipient of the major research awards in his field including the Hofheimer Prize from the American Psychiatric Association, the International Anna-Monika Prize for Research in Depression, the Edward A. Strecker Award, the Lieber Prize from NARSAD, the McAlpin Award, the Distinguished Service Award from NAMI, and the Research Award from the American Foundation for Suicide Prevention. He was the first recipient of the Psychiatrist of the Year from Psychiatric Times, and the Fawcett Humanitarian Award of the NDMDA. In 1998, he was elected President of the Psychiatric Research Society.
The author of 420 publications, Dr. Goodwin (with Kay Redfield Jamison, Ph.D.) wrote Manic-Depressive Illness, the first psychiatric text to win the “Best Medical Book” award from the Association of American Publishers. He is a Member of the Institute of Medicine of the National Academy of Sciences and a Fellow of the ACNP. He serves on the editorial boards of key scientific journals, including the Archives of General Psychiatry, the Journal of Clinical Psychopharmacology and is a founder of Psychiatry Research. He is one of five psychiatrists on the Current Contents list of the most frequently cited scientists in the world and one of twelve psychiatrists listed in The Best Doctors in the U.S.
In addition to his work at The George Washington University Medical Center and his private practice, Dr. Goodwin is the host of the award winning The Infinite Mind radio show. This one hour national weekly public radio program is dedicated to issues relating to the mind, the brain, and mental illness. The program is now carried in more than 150 markets. Its estimated 500,000 + listeners make it the most popular health show in public radio.
Dr. Husseini K. Manji
Dr. Husseini K. Manji is Chief of the Laboratory of Molecular Pathophysiology at the National Institute of Mental Health. He is a Professor of Psychiatry and Behavioral Neurosciences, and Pharmacology at Wayne State University School of Medicine. At Wayne State, he was the founding director of the Neuropsychiatric Research Unit, and the Founding Director of both the Schizophrenia and Mood Disorders Clinical Research Division at the Laboratory of Molecular Pathophysiology.
Dr. Manji was the 1992 winner of the prestigious A.E. Bennett Award for Psychiatric Research, and went on to win many other important awards, including the Ziskind-Somerfeld Research Award for Neuropsychiatric Research, the NARSAD Prize for Affective Disorders Research (Nola Maddox Falcone Prize) as well as the 2001 and 2002 NIH Special Act Awards.
Husseini Manji has published over 130 professional articles and has done elegant work elucidating the neuroprotective properties of mood stabilizers such as lithium and divalproex sodium. He is the Editor of Neuroscience Perspectives, Biological Psychiatry, and Translational Neuroscience, Psychopharmacology Bulletin. He is an Associate Editor of Bipolar Disorders: An International Journal of Psychiatry and Neurosciences.
Dr. Manji is currently a Member of the Scientific Advisory Board of the NIMH Bipolar Initiative and a Member of the NIMH Bipolar Disorder Systematic Treatment Enhancement Program Oversight Committee .
Husseini Manji’s current work on the molecular and cellular mechanisms of action of mood stabilizing agents is supported by major grants from both the NIMH and the Stanley Foundation.
Robert M. Post, M.D.
Robert M. Post, M.D. is one of the most widely-recognized names in the field of psychiatry. After graduating from Yale and completing a psychiatric residency at Massachusetts General Hospital, he finished a clinical fellowship at the National Institute of Mental Health in Bethesda, Maryland, where he soon was promoted to Unit and Section Chief and then Chief of the Biological Psychiatry Branch.
Throughout his distinguished career, he and his research group have focused on better understanding and developing new treatments for patients with refractory unipolar and bipolar illness. Two main areas of interest are anticonvulsant therapy and, most recently, repeated transcranial magnetic stimulation (rTMS).
Dr. Post was one of the first researchers to call for early treatment of a mood disorder and advanced the term “kindling”: the observation that if periods of cycling continue to occur unchecked, they will occur with greater and greater frequency.
Dr. Post and his group have won major research awards from the Society of Biological Psychiatry, the American Psychiatric Association (APA), the American College of Neuropsychopharmacolgy (ACNP), The Anna Monika Foundation, and The National Alliance for Research on Schizophrenia and Depression (NARSAD), among others. He serves on the editorial boards of more than ten prestigious journals and has published more than 900 scientific manuscripts.
Robert M. Post, M.D organized the Stanley Foundation Bipolar Network (1995-2002) which continues as the Bipolar Collaborative Network, focusing on developing effective long-term treatment approaches to this life-threatening recurrent affective disorder.
Dr. Robert Shprintzen
Dr. Robert Shprintzen is Professor of Otolaryngology and Communication Sciences at Upstate Medical University in Syracuse, New York, where he is the Director of of the Center for Diagnosis, Treatment and Study of Velo-Cardio-Facial Syndrome and the Center for Genetic Communication Disorders. He is recognized throughout the medical world for delineating four genetic diseases, several of which bear his name– most notably Velo-Cardio-Facial Syndrome (VCFS), commonly known as Shprintzen’s Syndrome.
Dr. Sprintzen was the first to see that the children with VCFS had a multitude of psychiatric symptoms, including psychosis and paranoia. This observation led to a collaboration with Dr. Demitri Papolos which resulted in the first systematic psychiatric diagnostic study of children with VCFS. The findings from this study, reported in the American Journal of Psychiatry, showed that over 70% of the VCFS children had bipolar spectrum disorders with multiple co-morbidities. Because VCFS arises from a specific genetic abnormality (a microdeletion on the short arm of chromosome 22) Dr. Sprintzen’s work has moved the field of behavioral genetics to actively investigate this region for candidate genes for a number of psychiatric and medical disorders, including bipolar disorder and schizophrenia, as well as certain behavioral traits such as poor modulation of aggression.
Robert Sprintzen is the author of five books, including four texts on genetic disorders associated with communication impairment and feeding disorders. He has been invited to lecture throughout the Europe, Africa, Asia, and Australia. He was the keynote speaker at the Mexican National Congress of Human Genetics in 1999, as well as the keynote speaker at a meeting sponsored by the World Health Organization in Zurich, Switzerland in 2000.
Prior to Dr. Sprintzen’s appointment at Upstate, he served as the Director of the Center for Craniofacial Disorders at Montefiore Medical Center and the Albert Einstein College of Medicine in New York City, where he was Professor of Plastic Surgery and Professor of Otolaryngology. In 1995, he helped found the Velo-Cardio-Facial Syndrome Educational Foundation, Inc. and has served as its Executive Director since its inception.
Martin H. Teicher, M.D., Ph.D.
Martin H. Teicher, M.D., Ph.D. is an Associate Professor of Psychiatry at Harvard Medical School and Director of the internationally-recognized Clinical Chronobiology Laboratory at McLean Hospital. His research studies range from inquiries into the molecular mechanisms of brain development, through cellular neuroanatomy, to regional neuropharmacology, up through studies of human behavior and brain imaging. A researcher and clinician with an unusual background in mathematics and technology, Dr. Teicher has succeeded in taking problems from the bedside to the laboratory bench and has then translated his findings back through clinical research trials to the bedside and to the marketplace. His capacity to attack problems from multiple levels in multiple domains has enabled him to pioneer new areas, to provide theoretical models and to develop new tools for clinicians.
He has been at the forefront of studies of actigraphy and motion analysis as tools for research in psychiatry and developed a new approach and software for non-linear multioscillator cosinor modeling. Using these tools, Dr. Teicher delineated and defined the different forms of rest-activity disturbance observed in many of the major psychiatric disorders including depression in children, adults and geriatric patients, ADHD, Post-traumatic stress disorder, and Alzheimer’s disease. He has written software for use in children or adults that can automatically generate a comprehensive clinical report on the subject’s level of activity, possible sleep continuity, and circadian patterns that will also indicate with a high level of confidence whether these patterns are most consistent with major unipolar depression, seasonal affective disorder, bipolar depression, mania, ADHD, schizophrenia, or the co-morbid presentation of these disorders.
Dr. Teicher has also collaborated with Perry Renshaw, MD, Ph.D. in the Brain Imaging Center at McLean Hospital to markedly advance the assessment of functional brain activity in psychiatric patients, particularly children. Dr. Teicher and Dr. Renshaw’s research teams devised and validated a new method for functional MRI imaging (T2-relaxometry) that provides indirect information about basal blood volume that is not only safer for developing brains, but also has higher resolution. Using this technique, this collaborative research team provided the first evidence that there is an abnormality in the paramagnetic properties of the striatum (specifically the putamen) in children with ADHD and are most likely the result of alterations in brain activity and cerebral blood volume. Furthermore, these changes correlate strongly with the child’s basal level of activity and inattention using infrared motion analysis. T2-relation time in the putamen changes significantly with drug treatment. The results of these studies were published in Nature Medicine, and serve as the basis for a pending patent.
In addition, Dr. Teicher has done seminal work on dopamine-receptor pruning, a developmental phenomenon that occurs between adolescence and adulthood. He is currently investigating the molecular mechanisms that regulate the overproduction and pruning of these dopamine receptors, along with the effects of exposure to early stress.
Dr. Martin Teicher has served on the Editorial Board of the Journal of Child and Adolescent Psychopharmacology since its inception, as has been a Committee Member of the Neurochemistry and Neuropharmocology Study Section of the National Institute of Mental Health. He is the author of over 100 articles in the scientific literature.